290 related articles for article (PubMed ID: 17176622)
1. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.
Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622
[TBL] [Abstract][Full Text] [Related]
2. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
[TBL] [Abstract][Full Text] [Related]
3. Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve.
Niioka T; Uno T; Yasui-Furukori N; Shimizu M; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Oct; 62(10):855-61. PubMed ID: 16915367
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
[TBL] [Abstract][Full Text] [Related]
5. Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Thyssen A; Solanki B; Treem W
Clin Ther; 2012 Jul; 34(7):1636-45. PubMed ID: 22748970
[TBL] [Abstract][Full Text] [Related]
6. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
[TBL] [Abstract][Full Text] [Related]
7. Application of a liquid chromatographic/tandem mass spectrometric method to a urinary excretion study of rabeprazole and two of its metabolites in healthy human urine.
Lu C; Jia Y; Song Y; Li X; Sun Y; Zhao J; Wang S; Shi L; Wen A; Ding L
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Apr; 988():75-80. PubMed ID: 25755073
[TBL] [Abstract][Full Text] [Related]
8. Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction.
Miura M; Tada H; Satoh S; Habuchi T; Suzuki T
J Pharm Biomed Anal; 2006 May; 41(2):565-70. PubMed ID: 16442771
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.
Sheng YC; Wang K; He YC; Yang J; Zheng QS
Eur J Clin Pharmacol; 2010 Nov; 66(11):1165-9. PubMed ID: 20838991
[TBL] [Abstract][Full Text] [Related]
11. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
12. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
13. Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.
Grabowski B; Lee RD
Clin Drug Investig; 2012 May; 32(5):319-32. PubMed ID: 22455762
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
Blight AR; Henney HR
Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905
[TBL] [Abstract][Full Text] [Related]
15. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
[TBL] [Abstract][Full Text] [Related]
16. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
18. Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis.
Hoyumpa AM; Trevino-Alanis H; Grimes I; Humphries TJ
Clin Ther; 1999 Apr; 21(4):691-701. PubMed ID: 10363734
[TBL] [Abstract][Full Text] [Related]
19. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
20. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
Park SH
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
[No Abstract] [Full Text] [Related]
[Next] [New Search]